Abstract
A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy.
The authors are grateful to Ms. Laurene Kelly for English revision of the manuscript.
References
1. GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH research society. J Clin Endocrinol Metab 2000;85:3990–3.Search in Google Scholar
2. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003;143:415–21.10.1067/S0022-3476(03)00246-4Search in Google Scholar
3. Flodh H. Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand Suppl 1986;325:1–9.10.1111/j.1651-2227.1986.tb10356.xSearch in Google Scholar
4. Kaplan SL, Underwood LE, August GP, Bell JJ, Blethen SL, et al. Clinical studies with recombinant DNA-derived methionyl human growth hormone deficient children. Lancet 1986;29:697–700.10.1016/S0140-6736(86)91098-6Search in Google Scholar
5. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, and stages of puberty. Arch Dis Child 1976;51:170–9.10.1136/adc.51.3.170Search in Google Scholar
6. Rehm H. The Experimentator, Proteinbiochemistry, Proteomics, 4th ed. Heidelberg: Spectrum Publishing, 2002:66–76.Search in Google Scholar
7. Underwood LE, Moore WV. Antibodies to growth hormone: measurement and meaning. Growth Genet Horm 1987;3: 1–3.Search in Google Scholar
8. Raben M. Treatment of pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18:901–3.10.1210/jcem-18-8-901Search in Google Scholar
9. Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, et al. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature 1979;281:544–8.10.1038/281544a0Search in Google Scholar
10. Lewis UJ. Growth hormone. What is it and what does it do? Trends Endocrinol Metab 1992;3:117–21.10.1016/1043-2760(92)90099-MSearch in Google Scholar
11. Milner RD, Barnes ND, Buckler JM, Carson DI, Hadden DR, et al. United Kingdom multicentre clinical trial of somatrem. Arch Child Dis 1987;62:776–9.10.1136/adc.62.8.776Search in Google Scholar PubMed PubMed Central
12. Strobl JS, Thomas MJ. Human growth hormone. Pharmacol Rev 1994;46:1–34.Search in Google Scholar
13. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin Endocrinol 1993;38: 137–42.10.1111/j.1365-2265.1993.tb00985.xSearch in Google Scholar PubMed
14. Riedl S, Frisch H. Effects of growth hormone (GH) and insulin-like growth factor-I therapy in patients with gene defects in the GH axis. J Pediatr Endocrinol Metab 2006;19: 229–36.10.1515/JPEM.2006.19.3.229Search in Google Scholar PubMed
15. Peterkova V, Arslanoglu I, Bolshova-Zubkovskaya E, Romer T, Zdravkovic D, et al. A randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency. Horm Res 2007;68:288–93.10.1159/000105494Search in Google Scholar PubMed
16. Romer T, Saenger P, Peter F, Walczak M, Le Bouc Y, et al. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study. Horm Res 2009;72:359–69.10.1159/000249164Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
